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Abstract 
Criteria that define low positive results on the COBAS® AmpliPrep/COBAS® TaqMan (CAP/CTM) HIV-
1 Qual test as inconclusive have been adopted by all academic centres in South Africa that conduct 
infant HIV PCR, following previous investigations that showed poor specificity of these results. 
Retesting all these specimens has considerable cost implications. It was therefore attempted to better 
characterise such inconclusive results, by comparing those that prove to be either negative or positive 
on follow-up testing. This retrospective, laboratory-based study found that 193 of 211 (91.5%) 
patients with with previous inconclusive results (defined as reported positive by CAP/CTM but with 
cycle threshold [Ct] values of >32 and/or fluorescence intensity [FI] values of <5) tested negative and 
only 18 (8.5%) positive using independently obtained follow-up samples after a median of 28 days). 
The only significant independent predictor of a later positive result was a higher FI value (3.326 vs. 
0.495, p<0.0001), whereas Ct values were not independently predictive. Specimens from patients 
negative on follow-up testing were qualitatively different from specimens that proved to be true 
positive. As the lower FI values in false-positive compared to true-positive results are probably 
indicative of a non-specific signal, the incorporation of stringent amplification slope criteria in the 
assay’s test definition file may improve correct classification and thus reduce the need for repeat 
testing of a large number of inconclusive specimens. 
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Introduction 
The COBAS® AmpliPrep/COBAS® TaqMan HIV-1 Qualitative test (CAP/CTM, Roche Molecular 
Systems Inc., Branchburg, NJ) is a total nucleic acid real-time polymerase chain reaction (PCR) 
assay that detects HIV-1 proviral DNA and HIV-1 RNA (Roche, 2007). The assay is well suited for 
early infant diagnostic testing in the South African context as it is a high-throughput, automated 
system, optimised to yield comparable amplification efficiencies for different HIV-1 group M subtypes 
and can test both whole EDTA blood and dried blood spot (DBS) samples. However, at the time of 
writing, the assay is classified as a “Research Use Only” assay without FDA approval or CE marking 
(Roche, 2007). 
As early antiretroviral therapy (ART) is proven to reduce HIV disease progression and early infant 
mortality by 75% and 76% respectively (Violari et al., 2008), current South African guidelines advise 
not to delay the initiation of ART in young children with a positive HIV PCR while awaiting the result of 
the baseline HIV-1 viral load test which also serves as confirmation (National Department of  
Health, 2010). In a high burden, limited resource setting like South Africa, reliable early diagnosis of 
infant HIV-1 infection with a single screening PCR is crucial as awaiting confirmatory test results can 
introduce treatment delays, especially in rural regions with poor access to healthcare. In 2011, 
between 248,869 and 284,023 HIV-exposed infants were born in South Africa (Sherman, 2012); this 
is in stark contrast to a resource rich setting like Canada, where the CAP/CTM assay is also used for 
infant diagnosis (Ontario province, [Public Health Ontario, 2011]) but as few as four infants were 
diagnosed with HIV infection countrywide in 2008 (Public Health Agency Canada, 2010). Settings like 
South Africa are not afforded the luxury of comprehensive diagnostic and confirmatory algorithms for 
a large part of the population, and false-positive screening HIV PCR results can thus pose a 
significant problem resulting in unnecessary exposure to ART, a waste of resources and diagnostic 
challenges later in life (Zanchetta et al., 2008).  
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With the decrease in recent years in the prevalence of infants who acquire HIV through mother-to-
child transmission (Moodley et al., 2013), diagnostic assays now require very high specificity to 
maintain a high positive predictive value. Previously, we reported poor specificity (97.1%) and positive 
predictive value (78.7%) of the CAP/CTM in testing DBS for HIV-1 infection compared to the 
reference method, defined as two AMPLICOR® HIV-1 DNA test v1.5 (Roche® Molecular Systems Inc., 
Branchburg, NJ) (“Amplicor”) results (Maritz et al., 2012). We concluded that the observed decreased 
specificity was unlikely to be due to superior sensitivity of the CAP/CTM but rather due to non-specific 
test signals, as results were not repeatable using a second DBS. Furthermore, the amplification 
curves of discordant (i.e. CAP/CTM positive, Amplicor negative) samples showed significantly lower 
fluorescence intensity (FI) and significantly higher cycle threshold (Ct) values compared to 
concordant positive samples. The low positive predictive value of the CAP/CTM was subsequently 
confirmed by another South African study (Feucht et al., 2012). 
To safeguard against the reporting of false positive results, we have, based on the abovementioned 
comparison, defined a set of criteria for the diagnosis of HIV-1 infection based on FI and Ct values as 
reported by the CAP/CTM system's Amplilink® software, to allow objective evaluation of the real-time 
curve measurements by different users. Subsequently all academic centres in South Africa have 
adopted these or similar criteria for result interpretation: in cases with absolute FI values below 5 
and/or Ct values higher than 32, results are reported as “inconclusive” and a follow-up sample to be 
obtained 10 to 14 days later is requested. In this study, the characteristics of samples with such 
inconclusive results that were followed up by testing a second, independently obtained sample are 
described. 
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Materials and Methods 
Objectives. To ascertain the true HIV status of samples yielding inconclusive results on the 
CAP/CTM, as defined by abovementioned criteria, through routine follow-up sample testing. It was 
further aimed to better characterise initially inconclusive CAP/CTM results by comparing FI and Ct 
values between samples that were proven to be either positive or negative on the follow-up 
specimen. 
Study design. This retrospective, laboratory-based study was performed at the Division of Medical 
Virology, National Health Laboratory Service Tygerberg, and was approved by the Human Research 
Ethics Committee of the University of Stellenbosch (approval number N11/09/283). 
Inclusion criteria. Patients under the age of two years with two or more blood samples sent for HIV-1 
PCR testing between January 2009 and May 2011, who had an initial inconclusive CAP/CTM result 
and a definitive result on follow-up. Eligible sample types included DBS and whole EDTA blood, as 
advised by the manufacturer (Roche, 2007), and as per laboratory standard operating procedure, 
EDTA samples older than five days were not tested. 
Exclusion criteria. Samples with measurable FI and Ct values, but that were reported as negative by 
the instrument, the significance of which is unknown (Maritz et al., 2012), and samples from which the 
hospital number, name or date of birth could not be matched. 
Sample selection. Data was extracted from the Laboratory Information System (LIS) of all samples, 
sent for diagnostic HIV PCR tests, between 1 January 2009 and 31 May 2011 in order to identify 
patients from whom more than one sample was sent. After extraction of the data, consecutive 
samples were identified by confirming surname, name, date of birth, and hospital number 
combinations of possible candidates. Patients who could not be matched due to missing data were 
excluded from the analysis. 
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Amplification curve characteristics of the CAP/CTM assay. As CAP/CTM measurement values itself 
are not routinely captured on the LIS, selected user-accessible parameters are routinely exported 
after each PCR run and archived. These measurements include sample laboratory numbers and FI 
and Ct values and were merged into a single database for this study using software macros to avoid 
possible transcription errors. The resulting database was merged with the patient database described 
above using software macros and using laboratory numbers as identifiers. After matching the LIS 
records with CAP/CTM records, all patient identifiers were deleted and unique identifiers were 
assigned to each sample pair. 
Definitions.  A negative HIV PCR was defined by a “Target not detected” report from the CAP/CTM, 
and a definite positive HIV PCR result was defined by a “1 – Positive” report from the CAP/CTM with 
a FI value of at least equal to five and a Ct value lower than or equal to 32 as per laboratory standard 
operating procedure (SOP). Samples with a “1 – Positive” report from the CAP/CTM with a FI value of 
less than five and / or a Ct value higher than 32 were reported as “inconclusive”. For the purposes of 
this study, inconclusive samples from patients who eventually tested positive are referred to as 
“inconclusive-positive”, and inconclusive samples from patients who eventually tested negative are 
referred to “inconclusive-negative”.   
Statistics. Descriptive statistics, Mann-Whitney U-tests and logistic regression analyses were 
performed. 
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Results  
Of a total of 211 sample sets, it was found that 193 inconclusive samples were negative on follow-up 
(91.5%) and 18 positive (8.5%, Table I, Figure I). A significantly lower median Ct value was observed 
for inconclusive-positive samples compared to inconclusive-negative samples; similarly, a 
significantly higher median FI value in inconclusive-positive samples compared to inconclusive-
negative samples was demonstrated (Table I). There was no significant difference in median time 
intervals between initial inconclusive and follow-up samples between the two groups, nor was the age 
of the patient at the time of the initial inconclusive PCR significantly different between the two groups. 
The impact of sample type (DBS or whole EDTA blood) on initial- or follow-up results could not be 
determined as very few DBS samples were tested during this comparison (Table I).  
When using both Ct and FI in logistic regression models to predict a definitive result of initially 
inconclusive samples, the adjusted model showed that FI is an independent significant predictor of 
follow-up sample result whereas Ct is no longer predictive when FI is included in the model (Table II). 
The fact that a high Ct value that predicts a false-positive result in a univariate model is no longer 
predictive when the FI value is included in the model, suggests that the amplification curves of false-
positive results are qualitatively different from those of true-positive results. Review of the 
amplification curves as reported by the CAP/CTM supports this suggestion, as the expected curve 
shape of an exponentially amplifying target is not evident in samples with low Ct values and low FI 
values (Figure II). It was further found that an FI value of equal to or greater than 2.98 would have a 
specificity of 98.9% and correctly predict the follow-up sample result in 95.8% of samples currently 
classified as “inconclusive”.  
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Discussion 
This study aimed to ascertain the HIV status of samples yielding inconclusive initial results using the 
CAP/CTM by using the results obtained from follow-up samples, and to better characterise 
inconclusive CAP/CTM results. As results generated by routine diagnostic screening for HIV-1 
infections and those of follow-up samples, where indicated, were evaluated retrospectively, it was not 
possible to compare CAP/CTM results to a gold standard.  
Significant differences in the FI and Ct values between inconclusive samples that eventually tested 
positive and those that tested negative were observed. Importantly, it was found that 91.5% of 
CAP/CTM positive samples with a Ct value of greater than 32 and/or a FI value of lower than 5 tested 
negative on a follow-up sample taken at a median of 28 days later. In a univariate model a low Ct 
value predicted positivity of a follow-up sample, however Ct values were no longer predictive of true 
positivity when used in a combined model with FI values. High FI values remained strongly predictive 
of true positivity in a combined model. Taken together, this suggests that true positive samples have 
steeper amplification slopes, suggesting true amplification, whereas false positive results have flat 
slopes (Figure II). 
The high rate of irreproducible positive results is alarming, especially considering that, had the 
previously formulated criteria not been applied, the false-positive result as reported by the CAP/CTM 
would have been accepted. This means that, in the absence of confirmatory test results (National 
Department of Health, 2010) during the period of study, 25% of patients commenced on ART based 
on the positive result would not have been infected with HIV.  This emphasises the need to define 
and use an indeterminate zone for result reporting.  
The findings of this study using predominantly EDTA samples are in support of the previous 
observation of false-positive result reporting from DBS. Similar observations have been made by 
others; a significantly increased frequency in detectable HIV-1 levels using the quantitative CAP/CTM 
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HIV-1 version 1 assay (which uses a comparable assay design to the CAP/CTM qualitative test) was 
reported in previously consistently-suppressed patients compared to the Roche Amplicor Monitor 
version 1.5 assay, which the authors speculated could be due to spurious signals caused by artefacts 
(Lima et al., 2009). Also, a study from a large South African hospital reported false positive HIV PCR 
results although the exact number generated by the CAP/CTM was not reported (Feucht et al., 2012).  
The reasons for flat amplification slopes of the inconclusive-negative samples are unclear. 
Suppressed HIV replication as a result of exposure to prolonged nevirapine monotherapy as part of a 
PMTCT strategy has been considered as an explanation for negative follow-up PCRs after initial low 
positive results; however it is considered unlikely that a single antiretroviral agent would result in 
abortive HIV infection in such a large number of patients. At the time of writing no data supporting this 
hypothesis have been published. Studies evaluating the peri- and postnatal history of infants with 
inconclusive PCR results may prove informative, but such data was not available during this 
evaluation. The lower volume of blood in DBS samples should also not have contributed to false-
negative follow-up results in this study as none of the follow-up tests were performed from DBS.  
Limitations of this study include the inability to correlate concurrent RNA viral load or integrated 
provirus load with initial or follow-up samples and the lack of comparison of all results to a gold 
standard or consensus result. Secondly, it is not possible to control for factors such as variability in 
sample characteristics or performance of specific components of the CAP/CTM instrument which 
could have contributed to discordant results on repeat samples. Assay and internal controls for each 
run were valid and it is therefore presumed that the instrument and assay performed optimally.  
As all assay runs including negative and positive controls were valid, and with more than 95% of all 
results being negative, low-level or intermittent contamination is an unlikely explanation. Carry-over 
contamination is regarded as unlikely as an evaluation of 40 random assay runs containing 
inconclusive samples included in this study did not reveal a spatial association with positive 
specimens in 33/40 runs, nor a temporal association. The manufacturer’s instructions regarding 
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sample preparation, sample loading and daily instrument decontamination were adhered to at all 
times, and amplicon contamination is eliminated by the use of uracil-N-glycosylase (Roche, 2007). All 
assay runs were performed by a small complement of experienced technologists trained by Roche in 
a single laboratory. The problem of inconclusive results is experienced in academic laboratories 
across South Africa, and as stated previously, all laboratories have adopted interpretation criteria for 
positive results. It is hard to believe that technical incompetence should account for similar findings 
across multiple laboratories. 
The findings of this study confirm that a large proportion of patients with initial results defined as 
being inconclusive are in fact negative. Although the current strategy of repeat testing patients with 
initial inconclusive results has significant cost implications and other disadvantages, we do not 
suggest that the criteria for triggering repeat testing be relaxed. Using a lower FI value cut-off might 
make reporting of inconclusive results more specific but insufficient data is available to establish 
whether this would not result in a decreased sensitivity. We believe that the only sound approach is to 
validate the test definition criteria of the assay, using raw amplification data, against a large data-bank 
of specimens that include inconclusive results with independently collected follow-up specimens. This 
is currently difficult as limited raw data are archived during routine assay runs. Another system, the 
Abbott m2000 RealTime HIV-1 assay, incorporates slope criteria (by setting criteria for the second 
derivative of the amplification curve, [Shain and Clemens, 2008]) in its test definition files and 
excludes specimens with flat slopes as being invalid. End users do not have access to assay test 
definition criteria and it is uncertain whether any slope criteria is applied, but the results presented 
here suggest that such criteria should either be included or, if already included, be more stringent in 
order to improve the specificity of the current assay and/or future assays. This is desirable as, apart 
from the cost implications of repeat testing, a delay in obtaining a definite result may delay initiation of 
antiretroviral therapy as soon as possible which children require to prevent HIV disease progression 
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and mortality (Violari et al., 2008). It is therefore pivotal to work towards improving the current test’s 
specificity.  
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Tables 
 
Table I. Comparison between inconclusive-negative and inconclusive-positive samples. 
Variable Inconclusive-
negative samples 
Inconclusive-
positive samples  
p value 
Number (%) 193 (91.5) 18 (8.5)  
Cycle threshold (Ct) valueα 35.4 (34.1-36.8) 32.6 (30.1-33.3)  p < 0.0001 
Fluorescence intensity (FI) valueα 0.495  
(0.399-0.663) 
3.326  
(2.064-4.370)  
p < 0.0001 
Interval between samples (days)α 29 (12 – 50)  28 (15 – 41) NS 
Age at initial inconclusive result (days)α 46 (42 – 67) 40 (29 – 88) NS 
DBS β 7 (3.6%) 0 (0%) - 
αMedian (interquartile range), Mann-Whitney U-test 
βnumber (%) 
NS = not significant 
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Table II. Comparison of Ct and FI of initial samples as predictors of a definitive result 
Model and variable Odds ratio (95% CI) p value (95% CI) 
Univariate model - Ct  0.655 (0.542 – 0.791) <0.001 
Univariate model - FI 5.348 (2.939 – 9.732) <0.001 
Adjusted modelα 
Ct 
FI 
 
1.208 (0.781 – 1.868) 
6.790 (2.878 – 16.020) 
 
0.397 
<0.001 
αAdjusted model included both Ct and FI 
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Figures 
 
 
Figure I. Sample selection process. 
19,843 HIV PCR results in 
laboratory database  
19,356 conclusive results (97.6%) 487 (2.5%) inconclusive results 
268 (55.0%) patients received 
follow-up PCR testing 
211 sample pairs with sufficient 
data for comparison 
 1316 (6.8%) Positive 18040 (93.2%) Negative 
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(a) 
 
 
(b) 
Figure II. Examples of a typical inconclusive-negative sample (a) and a positive sample (b). 
Amplification curves are shown as extracted from the archive of Amplilink® software. Target 
amplification curves are indicated by squares and internal control amplification curves by circles. 
 
